NCT06507657View on ClinicalTrials.gov

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

January 15, 2029

Study Completion Date

January 15, 2029

Conditions
HypertensionCardiovascular Diseases
Interventions
DRUG

empagliflozin

"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."

DRUG

Placebo tablet

"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."

Trial Locations (1)

55414

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER